Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Polycystic Ovary Syndrome 8Neoplasm Metastasis 5Breast Neoplasms 5Neoplasms 3Recurrence 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Obesity 2Multiple Myeloma 2Metabolic Diseases 2Leukemia, Lymphocytic, Chronic, B-Cell 2Insulin Resistance 2Infertility 2Glioblastoma 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Weight Loss 1Waldenstrom Macroglobulinemia 1Thrombocytopenia 1TP53 Y220C Mutation 1Splenomegaly 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Mycosis Fungoides 1Mouth Neoplasms 1

Interventions

Gemcitabine 2Taxes 1Radiotherapy, Conformal 1Metformin 1Ethiodized Oil 1Albumin-Bound Paclitaxel 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Pancreatic Adenocarcinoma × Metformin × Clear all
NCT02336087 2026-02-04

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

City of Hope Medical Center

Phase 1 Active not recruiting
21 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡